SEC Form 4 · accession 0001882909-26-000004
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandra Calvin
Officer — SVP, CHIEF ACCOUNTING OFFICER
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 9:29 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | M | 2,500 | $27.50 | A | 44,853 | D | |
| Common Stock | Sep 15, 2026 | M | 1,250 | $22.40 | A | 46,103 | D | |
| Common Stock | Sep 15, 2026 | M | 1,625 | $20.46 | A | 47,728 | D | |
| Common StockF2 | Sep 15, 2026 | S | 4,275 | $62.135 | D | 43,453 | D | |
| Common StockF3 | Sep 15, 2026 | S | 800 | $62.8481 | D | 42,653 | D | |
| Common StockF4 | Sep 15, 2026 | S | 300 | $63.6633 | D | 42,353 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F5 | $27.50 | Sep 15, 2026 | M | 2,500 | D | — | Jan 31, 2032 | Common Stock | 2,500 | 0 | D |
| Employee stock option (right to buy)F6 | $22.40 | Sep 15, 2026 | M | 1,250 | D | — | Jan 31, 2033 | Common Stock | 1,250 | 3,750 | D |
| Employee stock option (right to buy)F7 | $20.46 | Sep 15, 2026 | M | 1,625 | D | — | Jan 31, 2035 | Common Stock | 1,625 | 17,875 | D |
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The stock option is fully vested and exercisable.
- F6One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
- F7One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.